Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions by Yujun Tong, Xiaobing Fan, Huan Liu, Huan Liu, Tiantian Liang

Subjects: Get full text

Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis by Gennaro Gadaleta-Caldarola, Laura Lanotte, Stefania Infusino, Arianna Gadaleta-Caldarola, Francesca Matilde Schipilliti, Claudia Citrigno, Cataldo Petrarota, Antonio Cusmai, Alessandro Rizzo

Subjects: Get full text

Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer by Francesca Matilde Schipilliti, Denise Drittone, Federica Mazzuca, Daniele La Forgia, Deniz Can Guven, Alessandro Rizzo

Subjects: Get full text

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer by Mythili Shastry, Saya Jacob, Hope S. Rugo, Erika Hamilton

Subjects: Get full text